HK1077592A1 - 改進型fc融合蛋白質 - Google Patents
改進型fc融合蛋白質Info
- Publication number
- HK1077592A1 HK1077592A1 HK06100143.0A HK06100143A HK1077592A1 HK 1077592 A1 HK1077592 A1 HK 1077592A1 HK 06100143 A HK06100143 A HK 06100143A HK 1077592 A1 HK1077592 A1 HK 1077592A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- domain
- fusion proteins
- improved
- ligand
- receptor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Virology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Transplantation (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP03006949 | 2003-03-26 | ||
PCT/EP2004/003239 WO2004085478A2 (en) | 2003-03-26 | 2004-03-26 | Improved fc fusion proteins |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1077592A1 true HK1077592A1 (zh) | 2006-02-17 |
Family
ID=33040920
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK06100143.0A HK1077592A1 (zh) | 2003-03-26 | 2006-01-04 | 改進型fc融合蛋白質 |
Country Status (15)
Country | Link |
---|---|
US (2) | US8007813B2 (zh) |
EP (2) | EP1606318B1 (zh) |
JP (2) | JP4741464B2 (zh) |
AT (1) | ATE438662T1 (zh) |
AU (2) | AU2004224123A1 (zh) |
CA (2) | CA2520138C (zh) |
CY (1) | CY1109536T1 (zh) |
DE (1) | DE602004022390D1 (zh) |
DK (1) | DK1606318T3 (zh) |
ES (1) | ES2327409T3 (zh) |
HK (1) | HK1077592A1 (zh) |
PL (1) | PL1606318T3 (zh) |
PT (1) | PT1606318E (zh) |
SI (1) | SI1606318T1 (zh) |
WO (2) | WO2004085479A2 (zh) |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101094688B (zh) | 2004-09-13 | 2013-05-01 | 建新公司 | 多聚构建体 |
EP1959981B1 (en) * | 2005-02-03 | 2019-10-16 | Coda Therapeutics Limited | Anti-connexin 43 compounds for treating chronic wounds |
CN101384614A (zh) | 2005-08-15 | 2009-03-11 | 加利福尼亚大学董事会 | Vegf活化的fas配体 |
EP1973576B1 (en) * | 2005-11-28 | 2019-05-15 | Genmab A/S | Recombinant monovalent antibodies and methods for production thereof |
US20090286962A1 (en) * | 2005-12-20 | 2009-11-19 | Woolven Benjamin P | Chimeric antibodies with part new world primate binding regions |
NZ569988A (en) | 2006-02-01 | 2011-09-30 | Cephalon Australia Pty Ltd | Domain antibody construct which binds to human TNF-alpha and contains a modified hinge region sequence and a truncated CH1 domain |
CN101074261A (zh) * | 2006-04-30 | 2007-11-21 | 北京同为时代生物技术有限公司 | Trail受体1和/或trail受体2特异性抗体及其应用 |
ATE545704T1 (de) * | 2006-05-17 | 2012-03-15 | Uni Klinikum Tuebingen | Antientzündliches fusionsprotein |
PT2101877E (pt) * | 2006-12-28 | 2013-07-22 | Deutsches Krebsforsch | Neutralização de atividade de blocos de invasão cd95 de células de glioblastoma in vivo |
ES2565834T3 (es) | 2007-06-01 | 2016-04-07 | University Of Maryland, Baltimore | Agentes de unión a receptor de Fc de región constante de inmunoglobulina |
EP2540740B1 (en) | 2008-06-17 | 2014-09-10 | Apogenix GmbH | Multimeric TNF receptors |
JP5665739B2 (ja) * | 2008-07-14 | 2015-02-04 | ドイチェス クレープスフォルシュングスツェントルムDeutsches Krebsforschungszentrum | 炎症性疾患を治療するためのcd95インヒビターの使用 |
CN102892778B (zh) | 2010-02-19 | 2018-06-08 | 列日大学 | 用于治疗甲型流感病毒诱发的疾病、编码经修饰的Mx蛋白的多核苷酸、蛋白和转基因动物 |
MX368531B (es) | 2010-07-28 | 2019-10-07 | Gliknik Inc | Proteinas de fusion de fragmentos de proteinas humanas naturales para crear composiciones de fc de inmunoglobulinas multimerizadas ordenadamente. |
WO2012019128A1 (en) | 2010-08-06 | 2012-02-09 | Genzyme Corporation | Vegf antagonist compositions and uses thereof |
WO2012085111A1 (en) | 2010-12-23 | 2012-06-28 | F. Hoffmann-La Roche Ag | Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery |
TWI476001B (zh) | 2011-12-26 | 2015-03-11 | Ind Tech Res Inst | 三倍體Fc融合蛋白及其用途 |
WO2013112986A1 (en) * | 2012-01-27 | 2013-08-01 | Gliknik Inc. | Fusion proteins comprising igg2 hinge domains |
BR112014028368A2 (pt) * | 2012-06-27 | 2017-11-14 | Hoffmann La Roche | método de produção de conjugado de região fc de anticorpo, conjugado de região fc de anticorpo e formulação farmacêutica |
EP2867253B1 (en) | 2012-06-27 | 2016-09-14 | F. Hoffmann-La Roche AG | Method for selection and production of tailor-made highly selective and multi-specific targeting entities containing at least two different binding entities and uses thereof |
JP6297552B2 (ja) | 2012-07-18 | 2018-03-20 | アポジェニックス アーゲー | Mdsの治療のための、cd95シグナル伝達経路阻害剤 |
CN109897115A (zh) * | 2012-07-18 | 2019-06-18 | 阿珀吉尼科斯股份公司 | 包含CD95-Fc同种型的混合物的组合物 |
EP2885320A4 (en) | 2012-08-20 | 2016-04-06 | Gliknik Inc | MOLECULES WITH ANTIGEN-BINDING AND POLYVALENT FC GAMMA RECEPTOR BINDING ACTIVITY |
US10189887B2 (en) | 2014-04-17 | 2019-01-29 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Polypeptides and uses thereof for reducing CD95-mediated cell motility |
WO2016118577A1 (en) * | 2015-01-22 | 2016-07-28 | Medimmune, Llc | Thymosin-beta-four fusion proteins |
MX2017014140A (es) | 2015-05-04 | 2018-03-15 | Apogenix Ag | Proteinas agonistas receptoras cd40 de cadena simple. |
WO2017068180A1 (en) | 2015-10-23 | 2017-04-27 | Apogenix Ag | Single-chain light receptor agonist proteins |
JP6917368B2 (ja) | 2015-10-23 | 2021-08-11 | アポジェニックス アーゲー | 一本鎖cd27受容体アゴニストタンパク質 |
EP3464347B1 (en) | 2016-06-07 | 2023-05-31 | Gliknik Inc. | Cysteine-optimized stradomers |
US11155574B2 (en) | 2016-12-09 | 2021-10-26 | Gliknik Inc. | Manufacturing optimization of GL-2045, a multimerizing stradomer |
MX2021011608A (es) | 2019-03-29 | 2021-12-10 | Myst Therapeutics Llc | Metodos ex vivo para producir celulas t terapeuticas y composiciones y metodos afines. |
CN115023270A (zh) | 2019-11-27 | 2022-09-06 | 迈斯特治疗公司 | 使用调节剂产生肿瘤反应性t细胞组合物的方法 |
CN115427438A (zh) | 2020-02-27 | 2022-12-02 | 迈斯特治疗公司 | 肿瘤反应性t细胞的离体富集和扩增的方法及其相关组合物 |
GB202016058D0 (en) | 2020-10-09 | 2020-11-25 | Ucl Business Ltd | Therapeautic treatment |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5116964A (en) | 1989-02-23 | 1992-05-26 | Genentech, Inc. | Hybrid immunoglobulins |
US5830469A (en) * | 1993-10-14 | 1998-11-03 | Immunex Corporation | Fas antagonists and uses thereof |
DE4447484C2 (de) * | 1994-04-08 | 1997-07-17 | Deutsches Krebsforsch | Mittel zur Hemmung von Apoptose |
US6284236B1 (en) * | 1995-06-29 | 2001-09-04 | Immunex Corporation | Cytokine that induces apoptosis |
EP0965637B1 (en) | 1996-05-02 | 2005-07-20 | Mochida Pharmaceutical Co., Ltd. | Fas ANTIGEN DERIVATIVES |
CA2270423C (en) * | 1996-10-31 | 2009-09-15 | Mochida Pharmaceutical Co., Ltd. | Prophylactic/therapeutic agent |
US6072047A (en) * | 1997-02-13 | 2000-06-06 | Immunex Corporation | Receptor that binds trail |
DE69810091T2 (de) | 1997-02-21 | 2003-10-09 | Vlaams Interuniv Inst Biotech | Verwendung von interleukin-15 |
CA2301202A1 (en) * | 1997-08-15 | 1999-02-25 | Idun Pharmaceuticals, Inc. | Trail receptors, nucleic acids encoding the same, and methods of use thereof |
PL343847A1 (en) | 1998-03-30 | 2001-09-10 | Lilly Co Eli | Therapeutic applications of mature flint (mflint) polypeptides or opg3, a member of the tnf receptor superfamily |
US6472179B2 (en) | 1998-09-25 | 2002-10-29 | Regeneron Pharmaceuticals, Inc. | Receptor based antagonists and methods of making and using |
JP2002543151A (ja) * | 1999-05-04 | 2002-12-17 | ヒューマン ジノーム サイエンシーズ, インコーポレイテッド | 死ドメイン含有レセプター5 |
DE19959049A1 (de) | 1999-12-07 | 2001-06-28 | Deutsches Krebsforsch | Kombination von Verbindungen, welche die biologischen Wirkungen von TNF-alpha und CD95L hemmen |
DE19963859A1 (de) | 1999-12-30 | 2001-07-12 | Apotech Res & Dev Ltd | Bi- oder Oligomer eines Di-, Tri-, Quattro- oder Pentamers von rekombinanten Fusionsproteinen |
RU2363707C2 (ru) * | 2001-02-19 | 2009-08-10 | Мерк Патент Гмбх | Искусственные белки с пониженной иммуногенностью |
WO2002079415A2 (en) | 2001-03-30 | 2002-10-10 | Lexigen Pharmaceuticals Corp. | Reducing the immunogenicity of fusion proteins |
DE10122140A1 (de) | 2001-05-08 | 2002-11-28 | Apotech Res & Dev Ltd | Rekombinante Fusionsproteine und deren Trimere |
JP4309758B2 (ja) * | 2001-05-25 | 2009-08-05 | ヒューマン ジノーム サイエンシーズ, インコーポレイテッド | Trailレセプターに免疫特異的に結合する抗体 |
DE10160248A1 (de) | 2001-12-07 | 2003-06-26 | Alexander Cherkasky | Fusionsproteinen enthaltend Fc-Regionen |
-
2004
- 2004-03-26 DE DE602004022390T patent/DE602004022390D1/de not_active Expired - Lifetime
- 2004-03-26 EP EP04723552A patent/EP1606318B1/en not_active Expired - Lifetime
- 2004-03-26 US US10/551,004 patent/US8007813B2/en active Active
- 2004-03-26 JP JP2006504877A patent/JP4741464B2/ja not_active Expired - Lifetime
- 2004-03-26 PT PT04723552T patent/PT1606318E/pt unknown
- 2004-03-26 EP EP04723556A patent/EP1606319A2/en not_active Withdrawn
- 2004-03-26 PL PL04723552T patent/PL1606318T3/pl unknown
- 2004-03-26 AT AT04723552T patent/ATE438662T1/de active
- 2004-03-26 ES ES04723552T patent/ES2327409T3/es not_active Expired - Lifetime
- 2004-03-26 DK DK04723552T patent/DK1606318T3/da active
- 2004-03-26 CA CA2520138A patent/CA2520138C/en not_active Expired - Lifetime
- 2004-03-26 WO PCT/EP2004/003245 patent/WO2004085479A2/en not_active Application Discontinuation
- 2004-03-26 AU AU2004224123A patent/AU2004224123A1/en not_active Abandoned
- 2004-03-26 CA CA002520254A patent/CA2520254A1/en not_active Abandoned
- 2004-03-26 SI SI200431264T patent/SI1606318T1/sl unknown
- 2004-03-26 WO PCT/EP2004/003239 patent/WO2004085478A2/en active Application Filing
- 2004-03-26 JP JP2006504879A patent/JP2007533595A/ja active Pending
- 2004-03-26 AU AU2004224122A patent/AU2004224122A1/en not_active Abandoned
-
2006
- 2006-01-04 HK HK06100143.0A patent/HK1077592A1/zh unknown
-
2009
- 2009-10-29 CY CY20091101120T patent/CY1109536T1/el unknown
-
2011
- 2011-08-19 US US13/213,345 patent/US20110305697A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP1606318A2 (en) | 2005-12-21 |
EP1606319A2 (en) | 2005-12-21 |
WO2004085478A2 (en) | 2004-10-07 |
ATE438662T1 (de) | 2009-08-15 |
CA2520138C (en) | 2017-05-23 |
ES2327409T3 (es) | 2009-10-29 |
AU2004224123A1 (en) | 2004-10-07 |
JP2007524365A (ja) | 2007-08-30 |
PL1606318T3 (pl) | 2010-01-29 |
WO2004085478A3 (en) | 2005-01-06 |
CY1109536T1 (el) | 2014-08-13 |
SI1606318T1 (sl) | 2009-12-31 |
AU2004224122A1 (en) | 2004-10-07 |
WO2004085479A2 (en) | 2004-10-07 |
CA2520138A1 (en) | 2004-10-07 |
WO2004085479A3 (en) | 2004-11-25 |
DE602004022390D1 (de) | 2009-09-17 |
US20070269449A1 (en) | 2007-11-22 |
CA2520254A1 (en) | 2004-10-07 |
EP1606318B1 (en) | 2009-08-05 |
DK1606318T3 (da) | 2009-11-02 |
JP4741464B2 (ja) | 2011-08-03 |
JP2007533595A (ja) | 2007-11-22 |
PT1606318E (pt) | 2009-11-10 |
US20110305697A1 (en) | 2011-12-15 |
US8007813B2 (en) | 2011-08-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1077592A1 (zh) | 改進型fc融合蛋白質 | |
CY1108545T1 (el) | Πρωτεϊνες υπομοναδας υποδοχεα κυτοκινης θηλαστικου, σχετικα αντιδραστηρια και μεθοδοι | |
CY1112787T1 (el) | Πολλαπλομερη του υποδοχεα κυτοκινης ζcytor17 | |
BR0212256A (pt) | Proteìnas de fusão de transferrina modificadas | |
RS51318B (sr) | Varijante imunoglobulina i njihova upotreba | |
DE69918946D1 (de) | Rezeptoren für il-18 | |
WO2003034903A3 (en) | Psma antibodies and protein multimers | |
BR0314814A (pt) | Variantes otimizadas de fc e métodos para sua geração | |
NO2011003I1 (no) | Dimensk fusjonsprotein bestående av de ligandbindende cfomener av de ekstacellulære deler av human type I interieukm-1 reseptor (IL-1R1) og IL-1 reseptor hjelpeprotein bundet (IL-I-RAcP) bundet i tinje til Fc-delen av humant IgG | |
WO2004020404A3 (en) | Modified transferin-antibody fusion proteins | |
ATE473011T1 (de) | Modifizierte transferrin-fusionsproteine mit doppelten transferrin-amino- oder carboxy- terminalen domänen | |
ES2187954T3 (es) | Anticuerpos anti-integrina avb3 antagonistas. | |
CY1111097T1 (el) | Πρωτεϊνη δεσμευσης του υποδοχεα nogo | |
BR0314092A (pt) | proteìnas de fusão de transferrina modificadas | |
ATE464374T1 (de) | Assay zum schnellen nachweis vom humanen aktivierten protein c und hochspezifischer monoklonaler antikörper dagegen | |
NO20005637L (no) | Hybridprotein for å inhibere degranulasjon av mastocyter og anvendelsen derav | |
NZ547629A (en) | Antibodies binding to conformationally discriminating epitopes of human IGG Fc receptor IIb and IIb | |
DE50309342D1 (de) | Gemisch mindestens zweier fusionsproteine sowie ihre herstellung und verwendung | |
DE60330680D1 (de) | Transferrin-fusionsproteinbibliotheken | |
DK1572931T3 (da) | Fremgangsmåder og sammensætninger til modulering og påvisning af WISP-aktivitet | |
WO2005065711A3 (en) | Mammalian receptor proteins; related reagents and methods | |
WO2003027239A3 (en) | Melanin-concentrating hormone receptor antagonist binding protein | |
ATE466076T1 (de) | Gewebe transglutaminase |